Horton Capital discloses 12.6% stake in KORU Medical Systems (KRMD)

Rhea-AI Filing Summary

KORU Medical Systems, Inc. received an amended Schedule 13D from Horton Capital entities and Joseph M. Manko, Jr. updating their investment position. As of the close of business on February 13, 2026, Horton Capital Partners Fund, LP directly owns 5,062,498 shares of common stock, representing 10.93% of KORU Medical’s outstanding shares based on 46,322,655 shares reported as of November 12, 2025. Including shares held directly by Mr. Manko, his aggregate beneficial ownership is reported as 5,845,045 shares, or 12.62% of the company.

The amendment details multiple in-kind distributions of KORU Medical shares by Horton Capital funds to their limited partners and members, as well as periodic “Director Shares” issued to Horton Capital Partners Fund in consideration for Mr. Manko’s board service. The reporting persons state that the shares are held for investment purposes but may be increased or reduced over time and that they may engage with KORU Medical’s management, board, and other stockholders on issues such as capitalization, ownership structure, board composition, or operations.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 12)

KORU Medical Systems, Inc.

(Name of Issuer)

Common Stock, Par Value $0.01 Per Share

(Title of Class of Securities)

759910102

(CUSIP Number)

JOSEPH M. MANKO, JR.
HORTON CAPITAL PARTNERS, LLC, 1717 Arch Street, Suite 3740
Philadelphia, PA, 19103
(215) 399 5402

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

02/13/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 759910102

1

Name of reporting person

Horton Capital Partners Fund, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC, OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 5,062,498.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 5,062,498.00

11

Aggregate amount beneficially owned by each reporting person

5,062,498.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

10.93 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. 759910102

1

Name of reporting person

Horton Capital Partners, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC, OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 5,062,498.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 5,062,498.00

11

Aggregate amount beneficially owned by each reporting person

5,062,498.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

10.93 %

14

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13D

CUSIP No. 759910102

1

Name of reporting person

Horton Capital Management, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC, OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 5,062,498.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 5,062,498.00

11

Aggregate amount beneficially owned by each reporting person

5,062,498.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

10.93 %

14

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13D

CUSIP No. 759910102

1

Name of reporting person

Joseph M. Manko, Jr.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC, OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 782,547.00
8	Shared Voting Power 5,062,498.00
9	Sole Dispositive Power 782,547.00
10	Shared Dispositive Power 5,062,498.00

11

Aggregate amount beneficially owned by each reporting person

5,845,045.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

12.62 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, Par Value $0.01 Per Share
(b)	Name of Issuer: KORU Medical Systems, Inc.
(c)	Address of Issuer's Principal Executive Offices: 100 Corporate Drive, Mahwah, NEW JERSEY , 07430.
Item 1 Comment: This statement relates to shares of common stock, par value $0.01 per share ("Common Stock"), of Koru Medical Systems, Inc., a Delaware corporation (the "Issuer"). The address of the principal executive offices of the Issuer is 100 Corporate Drive, Mahwah, New Jersey. Horton Capital Partners Fund, LP, a Delaware limited partnership ("HCPF"), Horton Capital Partners LLC, a Delaware limited liability company ("HCP"), Horton Capital Management, LLC, a Delaware limited liability company ("HCM"), and Joseph M. Manko, Jr. ("Mr. Manko") filed Schedule 13D with the Securities and Exchange Commission (the "SEC") on May 23, 2017, as amended by Amendments Nos. 1 - 11 filed on December 4, 2017, December 21, 2017, March 16, 2018, September 20, 2018, December 21, 2018, January 29, 2020, August 20, 2020, April 6, 2021, February 24, 2023, December 29, 2023, and January 21, 2025 ("Schedule 13D"), to report their beneficial ownership of the shares of Common Stock of the Issuer. This Amendment No. 12 ("Amendment No. 12") is filed with the SEC to amend and supplement Schedule 13D.
Item 2.	Identity and Background
(a)	This statement is filed by HCPF, HCP, HCM, and Mr. Manko (Mr. Manko together with HCPF, HCP and HCM, the "Reporting Persons" and each a "Reporting Person"), with respect to shares of Common Stock of the Issuer.
(b)	The address of the principal office of each Reporting Person is 1717 Arch Street, Suite 3740, Philadelphia, PA 19103. The managing member of HCP and HCM is Mr. Joseph M. Manko, Jr.
(c)	The principal business of HCPF and HCP is purchasing, holding, and selling securities for investment purposes. The principal business of HCM is serving as the investment manager of HCPF. HCP is the general partner of HCPF. The principal occupation of Mr. Manko is serving as the managing member of HCM and HCP.
(d)	No Reporting Person has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	No Reporting Person has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	Mr. Manko is a citizen of the United States of America.
Item 3.	Source and Amount of Funds or Other Consideration
	The responses to Item 4 of this Amendment No. 12 are incorporated herein by reference. Unless otherwise disclosed below, the Reporting Persons used working capital to acquire shares of Common Stock.
Item 4.	Purpose of Transaction
	The Reporting Persons acquired the shares of Common Stock for investment purposes. The purpose of this Amendment No. 12 is to disclose changes in the beneficial ownership of the shares of Common Stock held by the Reporting Persons including: (i) the issuance of shares of Common Stock to HCPF in consideration for Mr. Manko's service as a director of the Issuer (the "Director Shares"); (ii) that HCPF transferred shares of Common Stock to certain of its limited partners; and (iii) that HCP transferred shares of Common Stock to certain of its members, including Mr. Manko. On January 10, 2024, Horton Freedom, L.P., ("Horton Freedom") in accordance with its terms, transferred 453,231 shares of Common Stock to certain of its limited partners, representing the remaining pro-rata in-kind distribution in respect of such limited partners' interests in Horton Freedom. As a result, as of January 10, 2024, Horton Freedom held 0 shares of Common Stock. On February 15, 2024, HCPF, in accordance with its terms, transferred 27,700 shares of Common Stock to a limited partner, representing a pro-rata in-kind distribution in respect of such limited partner's interest in HCPF. On March 31, 2024, 6,329 Director Shares were issued to HCPF; on June 30, 2024, 5,545 Director Shares were issued to HCPF; on September 30, 2024, 5,454 Director Shares were issued to HCPF; and on December 31, 2024, 3,937 Director Shares were issued to HCPF. On July 24, 2024, HCPF, in accordance with its terms, transferred 721,781 shares of Common Stock to a limited partner, representing a pro-rata in-kind distribution in respect of such limited partner's interest in HCPF. On January 21, 2025, HCPF, in accordance with its terms, transferred 1,000,000 shares of Common Stock to certain of its limited partners, including HCP, representing a pro-rata in-kind distribution in respect of such limited partners' interest in HCPF. HCP subsequently transferred 1,000,000 shares of Common Stock received from HCPF to its members, including 351,948 shares of Common Stock to Mr. Manko. On March 31, 2025, 5,870 Director Shares were issued to HCPF; on June 30, 2025, 4,189 Director Shares were issued to HCPF; on September 30, 2025, 3,916 Director Shares were issued to HCPF; and on December 31, 2025, 2,581 Director Shares were issued to HCPF. On May 20, 2025, HCPF, in accordance with its terms, transferred 14,317 shares of Common Stock to a limited partner, representing a pro-rata in-kind distribution in respect of such limited partner's interest in HCPF. On November 26, 2025, HCPF, in accordance with its terms, transferred 41,000 shares of Common Stock to a limited partner, representing a pro-rata in-kind distribution in respect of such limited partner's interest in HCPF. On February 13, 2026, HCPF, in accordance with its terms, transferred 770,418 shares of Common Stock to certain of its limited partners, including HCP, representing a pro-rata in-kind distribution in respect of such limited partners' interest in HCPF. HCP subsequently transferred 750,000 shares of Common Stock received from HCPF to its members, including 282,347 shares of Common Stock to Mr. Manko. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of shares of Common Stock at prices that would make the purchase or sale of such shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of shares of Common Stock on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable. No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of the form of Schedule 13D, except as set forth herein, or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position and investment strategy, the price levels of the shares of Common Stock of the Issuer, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, engaging in additional communications with management and the Board of the Issuer, engaging in discussions with stockholders of the Issuer and others about the Issuer and the Reporting Persons' investment, making proposals to the Issuer concerning changes to the capitalization, ownership structure, board structure (including board composition) or operations of the Issuer, purchasing additional shares of Common Stock, selling some or all of their shares of Common Stock, or changing their intention with respect to any and all matters referred to in Item 4. Notwithstanding any of the foregoing, the Reporting Persons may at any time modify, change, abandon, or replace, some or all of the foregoing purposes and plans and discussions relating thereto or discontinue or re-continue such modifications, changes, abandonments, or replacements at any time.
Item 5.	Interest in Securities of the Issuer
(a)	See the Reporting Persons section of this Schedule 13D/A for the aggregate number of Common Shares and percentages of the Common Shares beneficially owned by each of the Reporting Persons. The percentages used herein are calculated based upon 46,322,655 shares of Common Stock issued and outstanding as of November 12, 2025, pursuant to the Quarterly Report on Form 10-Q filed by the Issuer with the SEC on November 12, 2025. As of the close of business on February 13, 2026: HCPF owns directly 5,062,498 shares of Common Stock. HCM maintains discretionary investment and voting authority with respect to 5,062,498 shares of Common Stock held by HCPF. HCP may be deemed to be the beneficial owner of such shares of Common Stock because, in the event HCM's investment advisory agreement with respect to such shares of Common Stock are terminated, HCP has the right to assume HCM's discretionary investment and voting authority with respect to such shares of Common Stock. HCP is the general partner of HCPF. Mr. Manko owns directly 782,547 shares of Common Stock. Mr. Manko is the managing member of both HCM and HCP and may be deemed to be the beneficial owner of the shares of Common Stock held by HCPF. Each of HCM, HCP, and Mr. Manko disclaims beneficial ownership of the shares of Common Stock held by HCPF.
(b)	See the Reporting Persons section of this Schedule 13D/A for the number of Common Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition. As of the close of business on February 13, 2026: HCPF owns directly 5,062,498 shares of Common Stock. HCM maintains discretionary investment and voting authority with respect to 5,062,498 shares of Common Stock held by HCPF. HCP may be deemed to be the beneficial owner of such shares of Common Stock because, in the event HCM's investment advisory agreement with respect to such shares of Common Stock are terminated, HCP has the right to assume HCM's discretionary investment and voting authority with respect to such shares of Common Stock. HCP is the general partner of HCPF. Mr. Manko owns directly 782,547 shares of Common Stock. Mr. Manko is the managing member of both HCM and HCP and may be deemed to be the beneficial owner of the shares of Common Stock held by HCPF. Each of HCM, HCP, and Mr. Manko disclaims beneficial ownership of the shares of Common Stock held by HCPF.
(c)	HCPF transferred 750,000 shares to HCP on February 13, 2026. HCP received and transferred 750,000 shares to its members on February 13, 2026. HCM has not entered into any transactions in the securities of the Issuer during the past 60 days. Mr. Manko received 282,347 shares from HCP on February 13, 2026.
(d)	No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Mr. Manko is a member of the Issuer's Board of Directors. The Reporting Persons have entered into a Joint Filing Agreement, attached hereto as Exhibit 1, pursuant to which they have agreed to file this Amendment No. 12 jointly in accordance with the provisions of Rule 13d-1(k) of the Act. The responses to Items 3, 4, and 5 of this Amendment No. 12 are incorporated herein by reference. Other than as described herein, there are no contracts, arrangements, understandings, or relationships among the Reporting Persons, or between the Reporting Persons and any other person, with respect to the securities of the Issuer.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 1 - Joint Filing Agreement, dated February 13, 2026. Exhibit 2 - Securities Purchase Agreement dated, August 8, 2014, between the Issuer and HCPF and the Warrant, dated August 8, 2014, incorporated by reference to Exhibit 4.1 of the Issuer's Annual Report on Form 10-K filed by the Issuer on May 8, 2015. Exhibit 3 - Common Stock Purchase Agreement, dated as of December 17, 2018, by and among the Issuer, the Sellers named therein and the Purchasers named therein, incorporated by reference to Exhibit 10.1 of the Issuer's Current Report on Form 8-K filed by the Issuer on December 17, 2018.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Horton Capital Partners Fund, LP

Signature:	/s/ Joseph M. Manko, Jr.
Name/Title:	Joseph M. Manko, Jr./Managing Member of Horton Capital Partners, LLC, the General Partner of Horton Capital Partners Fund, LP
Date:	02/13/2026

Horton Capital Partners, LLC

Signature:	/s/ Joseph M. Manko, Jr.
Name/Title:	Joseph M. Manko, Jr./Managing Member
Date:	02/13/2026

Horton Capital Management, LLC

Signature:	/s/ Joseph M. Manko, Jr.
Name/Title:	Joseph M. Manko, Jr./Managing Member
Date:	02/13/2026

Joseph M. Manko, Jr.

Signature:	/s/ Joseph M. Manko, Jr.
Name/Title:	Joseph M. Manko, Jr.
Date:	02/13/2026

FAQ

What ownership stake in KORU Medical Systems (KRMD) does Horton Capital report?

Horton Capital Partners Fund, LP reports directly owning 5,062,498 KORU Medical shares, equal to 10.93% of the company’s outstanding common stock. Including shares held directly by Joseph M. Manko, Jr., aggregate beneficial ownership is disclosed at 12.62% of KORU Medical.

How many KORU Medical (KRMD) shares does Joseph M. Manko, Jr. personally hold?

Joseph M. Manko, Jr. reports directly owning 782,547 KORU Medical common shares. He is also managing member of Horton Capital entities that may be deemed to beneficially own additional shares, bringing his aggregate beneficial ownership to 5,845,045 shares, or 12.62% of the company.

What changes does Amendment No. 12 report for Horton Capital’s KORU Medical (KRMD) position?

Amendment No. 12 reports in-kind share distributions from Horton Capital funds to limited partners and members, and periodic “Director Shares” issued to Horton Capital Partners Fund. It also discloses February 13, 2026 transfers, including 770,418 shares distributed by Horton Capital Partners Fund and 282,347 shares received by Mr. Manko.

Why was KORU Medical (KRMD) stock issued as Director Shares to Horton Capital?

KORU Medical issued “Director Shares” of common stock to Horton Capital Partners Fund as consideration for Joseph M. Manko, Jr.’s service on the company’s board. These issuances occurred quarterly during 2024 and 2025, with specific share amounts disclosed for each quarter-end date.

How is the KORU Medical (KRMD) ownership percentage calculated in this Schedule 13D/A?

Ownership percentages are calculated using 46,322,655 KORU Medical common shares reported as outstanding as of November 12, 2025. Based on this figure, Horton Capital Partners Fund’s 5,062,498 shares equal 10.93%, while Mr. Manko’s aggregate 5,845,045 shares equal 12.62% of the company.

What future actions do Horton Capital and Joseph M. Manko, Jr. contemplate regarding KORU Medical (KRMD)?

The reporting persons state they acquired KORU Medical shares for investment purposes and may buy or sell shares over time. They may also communicate with management, the board, or stockholders and could make proposals regarding capitalization, ownership structure, board composition, or company operations.